Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 14
- Registration Number
- NCT00130507
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
- First Posted Date
- 2004-03-15
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00004163
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Yale-New Haven Hospital, New Haven, Connecticut, United States
Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT00053339
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.